Reduction of Stress and Fatigue Clinical Trial
We hope that with the drug, patients obtain reduced levels of stress and fatigue, according to the scales that we use in the study. Hopefully the results of the treated group are significantly higher than the control group (placebo).
| Status | Suspended |
| Enrollment | 300 |
| Est. completion date | December 2010 |
| Est. primary completion date | November 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Agree with all study procedures, signing the IC in two ways; - Patients older than 18 years, male or female, regardless of ethnicity or social class; - Presence of mild to moderate stress, confirmed with the Stress Symptom Inventory (ISS); - Presence of staff fatigue with a score greater than 36 according to the Fatigue Severity Scale (FSS). Exclusion Criteria: Constitute exclusion criteria of the study: - Participation in clinical trials in the 12 months preceding the survey; - Current treatment with drugs that are stimulants or central nervous system depressants such as hypnotics, anxiolytics, antipsychotics, antidepressants, statins and muscle relaxants; - Alternative therapies that scientifically, or have no influence in the tables of stress or fatigue as color therapy, acupuncture or relaxing massages; - Treatment psychotherapeutic medication or not; - Current treatment or prediction of treatment with oral anticoagulants (due to interaction with the tocopherol); - Women who are pregnant or lactating; - Patients with lactose intolerance; - Patients allergic to soy or peanuts; - chronic renal failure; - Patients using other multivitamins or individual vitamins such as vitamin D and / or A. - Chronic alcoholism; - Patients with clinical diagnosis of diseases causing severe chronic pain or adversely affect the clinical interpretation as fibromyalgia, multiple sclerosis, neuropathies and myopathies; - Patients with hypothyroidism or hyperthyreosis diagnosed clinically; - Patient history and physical examination suggestive of severe hepatorenal failure; - Patients with decompensated diabetes mellitus (fasting glucose above 180 mg / dL); - Patients undergoing treatment for cancer; - Amendment of the routine of life during the study as early vacation or suspected change in working hours; - Patients with complaints of excessive sleepiness caused by organic disease such as sleep apnea and morbid obesity (BMI above 35); - History of hypersensitivity to any component of the product under investigation; - Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| L.A.L Clinica Pesquisa e Desenvolvimento Ltda. |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Reduction of stress and fatigue | Stress: ISS Scale will be assessed by the scale - Inventory of Symptoms of Stress in the time selection / screening, 14 and 28 days ± 2 days of treatment. Fatigue: FSS Scale will be assessed by the scale - Fatigue Severity Scale Selection in The Times / Triage, 14 and 28 days ± 2 days of treatment. |
14 and 28 days | No |
| Secondary | Quality of life and Sexual Function | c) Quality of life: the quality of life of patients will be assessed using the Short Form 36 questionnaire (SF-36) during the period included 14 and 28 days ± 2 days of treatment. d) Sexual function: evaluation of possible changes in libido or sexual performance that this drug will develop will be made by direct questioning by the doctor to the patient inclusion period 14 and 28 days ± 2 days of treatment. |
14 and 28 days | No |